Tiverton Asset Management LLC acquired a new stake in Zogenix, Inc. (NASDAQ:ZGNX) during the 1st quarter, HoldingsChannel reports. The fund acquired 20,000 shares of the company’s stock, valued at approximately $801,000.
Several other institutional investors and hedge funds also recently modified their holdings of the company. California Public Employees Retirement System grew its stake in shares of Zogenix by 2.4% in the fourth quarter. California Public Employees Retirement System now owns 59,150 shares of the company’s stock valued at $2,369,000 after acquiring an additional 1,400 shares in the last quarter. Rhumbline Advisers grew its stake in shares of Zogenix by 5.1% in the first quarter. Rhumbline Advisers now owns 34,097 shares of the company’s stock valued at $1,366,000 after acquiring an additional 1,659 shares in the last quarter. Kazazian Asset Management LLC grew its stake in shares of Zogenix by 11.6% in the fourth quarter. Kazazian Asset Management LLC now owns 16,268 shares of the company’s stock valued at $652,000 after acquiring an additional 1,686 shares in the last quarter. Schwab Charles Investment Management Inc. grew its stake in shares of Zogenix by 2.8% in the first quarter. Schwab Charles Investment Management Inc. now owns 69,397 shares of the company’s stock valued at $2,780,000 after acquiring an additional 1,900 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new position in shares of Zogenix in the first quarter valued at about $100,000.
Several equities analysts recently commented on ZGNX shares. ValuEngine upgraded shares of Zogenix from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. Zacks Investment Research upgraded shares of Zogenix from a “hold” rating to a “buy” rating and set a $50.00 price objective on the stock in a research note on Thursday, March 15th. Leerink Swann increased their price objective on shares of Zogenix from $50.00 to $54.00 and gave the stock an “outperform” rating in a research note on Friday, February 23rd. Mizuho reiterated a “buy” rating and set a $51.00 price objective on shares of Zogenix in a research note on Thursday, February 1st. Finally, BidaskClub downgraded shares of Zogenix from a “buy” rating to a “hold” rating in a research note on Tuesday, April 10th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $53.20.
Shares of Zogenix opened at $39.70 on Thursday, Marketbeat.com reports. The stock has a market cap of $1.39 billion, a price-to-earnings ratio of -9.88 and a beta of 1.70. Zogenix, Inc. has a 12-month low of $39.05 and a 12-month high of $39.50.
Zogenix (NASDAQ:ZGNX) last announced its quarterly earnings data on Wednesday, May 9th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.13). During the same period in the previous year, the business posted ($0.86) EPS. equities analysts predict that Zogenix, Inc. will post -3.89 EPS for the current fiscal year.
In other Zogenix news, Director Roger Hawley sold 35,000 shares of the stock in a transaction dated Tuesday, March 13th. The shares were sold at an average price of $44.71, for a total transaction of $1,564,850.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 5.00% of the company’s stock.
Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.
Want to see what other hedge funds are holding ZGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zogenix, Inc. (NASDAQ:ZGNX).
Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.